期刊文献+

人细小病毒B19结构蛋白VP1的表达及IgM间接ELISA检测方法的初步建立 被引量:1

Expression of structural protein VP1 of human parvovirus B19 and preliminary development of indirect ELISA for IgM
原文传递
导出
摘要 目的原核表达并纯化人细小病毒B19(Human parvovirus B19,HPVB19)结构蛋白VP1,并初步建立IgM ELISA检测方法,用于B19病毒感染的检测。方法采用PCR法从B19 IgM阳性血清中扩增VP1基因片段,亚克隆至表达载体pGEX-2T中,构建重组表达质粒pGEX-2T-VP1,转化大肠杆菌BL21(DE3),IPTG诱导表达。表达产物经疏水纯化后进行Western blot分析。以纯化的重组蛋白包被酶标板,建立IgM间接ELISA检测方法,确定Cut-off值,并进行初步应用。结果重组原核表达质粒经双酶切鉴定构建正确;表达的重组融合蛋白相对分子质量为61 000,主要以包涵体形式存在,纯度为96%,可与B19 IgG阳性血清发生特异性反应;建立的间接ELISA方法 Cut-off值为0.102,灵敏度为91.7%,特异性为98.6%,与对照试剂检测结果的符合率为97.1%;用建立的方法检测4 500份健康献血者及39份类风湿性关节炎患者血清的B19 IgM抗体,阳性率分别为1.04%和10.3%。结论原核表达并纯化了HPVB19 VP1蛋白,并初步建立了IgM间接ELISA检测方法,为B19病毒感染的早期诊断提供了参考。 Objective To express the structural protein VP1 of human parvovirus B19(HPVB19) in prokaryotic cells,purify the expressed product,and preliminarily develop an ELISA method for IgM to monitor HPVB19 infection.Methods VP1 gene fragment was amplified by PCR and subcloned into prokaryotic expression vector pGEX-2T.The constructed recombinant plasmid pGEX-2T-VP1 was transformed to E.coli BL21(DE3) and induced with IPTG.The expressed product was purified by hydrophobic chromatography and analyzed by Western blot.An indirect ELISA method for IgM was developed by coating the microtiter plate with the purified recombinant protein,then determined for cut-off value and applied preliminarily.Results Restriction analysis proved that recombinant plasmid pGEX-2T-VP1 was constructed correctly.The expressed recombinant fusion protein,with a relative molecular mass of 61 000,mainly existed in a form of inclusion body,which reached a purity of 96% and showed specific reaction with B19 IgG positive serum.The cut-off value,sensitivity and specificity of the developed ELISA method were 0.102,91.7% and 98.6% respectively.The coincidence rate of determination results by the developed kit and control kit was 97.1%.A total of 4 500 serum samples from healthy donors and 39 from patients with rheumatoid arthritis were determined by the developed ELISA method,in which the positive rates of B19 IgM were 1.04% and 10.3% respectively.Conclusion The VP1 protein of HPVB19 was expressed in prokaryotic cells and purified,and an indirect ELISA method for IgM was preliminarily developed,which provided a reference for early diagnosis of HPVB19 infection
出处 《中国生物制品学杂志》 CAS CSCD 2012年第3期345-348,356,共5页 Chinese Journal of Biologicals
关键词 细小病毒B19 VP1蛋白 酶联免疫吸附测定 类风湿关节炎 Parvovirus B19 human VP1 protein Enzyme-linked immunosorbent assay(ELISA) Rheumatoid arthritis
  • 相关文献

参考文献16

  • 1Kelly HA,Siebert D,Hammond R,et al.The age-specific preva-lence of human parvovirus immunity in Victoria,Australia com-pared with other parts of the world[J].Epidemiol Infect,2000,124(3):449-457.
  • 2Tsujimura M,Matsushita K,Shiraki H,et al.Human parvovirusB19 infection in blood donors[J].Vox Sang,1995,69(3):206-212.
  • 3Wan ZH,Zhi N,Wong S,et al.Human parvovirus B19 causescell cycle arrest of human erythroid progenitors via deregulation ofthe E2F family of transcription factors[J].J Clin Invest,2010,120(10):3530-3544.
  • 4Tolfvenstam T,Broliden K.Parvovirus B19 infection[J].SeminFetal Neonatal Med,2009,14(4):218-221.
  • 5Castagna L,Furst S,El Cheikh J,et al.Parvovirus B19 as an e-tiological agent of acute pleuro-pericarditis[J].Bone MarrowTransplant,2011,46(2):317-318.
  • 6Heegaard ED,Brown KE.Human parvovirus B19[J].Clin Micro-biol Rev,2002,15(3):485-505.
  • 7Modrow S,Dorsch S.Antibody responses in parvovirus B19 in-fected patients[J].Pathol Bio(l Paris),2002,50(5):326-331.
  • 8Tzang BS,Tsay GJ,Lee YJ,et al.The association of VP1 uniqueregion protein in acute parvovirus B19 infection and anti-phospho-lipid antibody production[J].Clin Chim Acta,2007,378(1-2):59-65.
  • 9Tzang BS,Lee YJ,Yang TP,et al.Induction of antiphospholipidantibodies and antiphospholipid syndrome-like autoimmunity innaive mice with antibody against human parvovirus B19 VP1 u-nique region protein[J].Clin Chim Acta,2007,382(1-2):31-36.
  • 10丁景春,陈庆平,张薇,张静,熊秀莲.类风湿关节炎的发生及疾病活动与人类微小病毒B19感染的相关性[J].中国临床康复,2003,7(27):3750-3750. 被引量:2

二级参考文献32

  • 1Cossart YE, Field AM, Cant B, et al. Parvovirus-like particles in human sera. Lancet, 1975, 1 (7898): 72-73.
  • 2Schmidt I, Blumel J, Seitz H, et al. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang, 2001, 81 (4): 228-235.
  • 3Parsyan A, Canodti D. Human erythrovirus B19 and blood transfusion-an update. Transfus Med, 2007, 17 (4): 263-278.
  • 4Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science, 1993, 262 (5130): 114- 117.
  • 5Kaufmann B, Simpson AA, Rossmann MG. The structure of human parvovirus B19. Proc Natl Acad Sci USA, 2004, 101 (32): 11628- 11633.
  • 6Dorsch S, Liebisch G, Kaufmann B, et al. The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol, 2002, 76 ( 4 ): 2014-2018.
  • 7Heegaard ED, Brown K. Human parvovirus B19. Clin Microbiol Rev, 2002, 15 (3): 485-505.
  • 8Zhi N, Mills IP, Lu J, et al. Molecular and functional analysis of a human parvovirus B19 infectious clone demostrates essential roles for NS1, VP1 and the 11-kilodalton protein in virus replication and infectivity. J Virol, 2006, 80 (12): 5941-5850.
  • 9Azzi A, Morfini M, Mannucci PM. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev, 1999, 13 (3): 194-204.
  • 10Brown KE, Young NS, Airing BM, et al. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion, 2001, 41 ( 1 ): 130-135.

共引文献4

同被引文献30

  • 1曹玉红,张光运,张国成,丁翠玲,曹艳华,杨欣伟,沈青.人细小病毒B19感染与小儿川崎病的关系[J].第四军医大学学报,2005,26(8):714-715. 被引量:7
  • 2Reid DM, Reid TM, Brown T, et al. Human parvovirus-associated arthritis :a clinical and laboratory description[J]. Lancet, 1985,1 (8426) : 422-425.
  • 3Leads from the MMWR. Risks associated with human parvovirus B19 infection[J]. JAMA, 1989,261 (10) : 1406-1408.
  • 4Virus taxonomy update. The International Committee on Taxonomy of Viruses[J]. Arch Virol, 1993,133 (3/4) :491-495.
  • 5Cossart YE, Field AM, Cant B, et al. Parvovirus-like particles in human sera[J]. Lancet, 1975,1 (7898) :72-73.
  • 6Siegl G, Bates RC, Berns KI, et al. Characteristics and taxonomy of Parvoviridae[J]. Intervirology, 1985,23 (2) : 61-73.
  • 7Koppelman MH, Cuypers HT, Emrieh T, et al. Quantitative real- time detection of parvovirus B 19 DNA in plasma[J]. Transfusion, 2004,44 ( 1 ) : 97-103.
  • 8Wee WW, Kanagalingam D. The use of anti-D immunoglobulins for rhesus prophylaxis : audit on knowledge and practices among obstetricians[J]. Singapore Med J, 2009,50( 11 ) : 1054-1057.
  • 9Nunoue T, Kusuhara K, Hara T. Human fetal infection with par- vovirus B19:maternal infection time in gestation, viral persis- tence and fetal prognosis[J]. Pediatr Infect Dis J, 2002,21 (12) : 1133-1136.
  • 10Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mor- tality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases[J]. Prenat Diagn,2004,24 (7) :513-518.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部